Difelikefalin Dimer Impurity 1 features a higher-order peptide association, often through intermolecular coupling or condensation. Dimerization modifies hydrodynamic radius, conformational ensemble, and binding characteristics. Researchers monitor its formation to understand aggregation pathways and synthetic side reactions. Uses include analytical-method stress testing, impurity mapping, and peptide-stability investigations.
CAT No: Z10-101-203
Synonyms/Alias:1-(N2-D-phenylalanyl-D-phenylalanyl-D-leucyl-N6-(1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-4-aminopiperidine-4-carbonyl)-D-lysyl)-4-aminopiperidine-4-carboxylic acid; 4-amino-1-((R)-6-(4-amino-1-((R)-6-amino-2-((R)-2-((R)-2-((R)-2-amino-3-phenylpropanamido)-3-phenylpropanamido)-4-methylpentanamido)hexanoyl)piperidine-4-carboxamido)-2-((R)-2-((R)-2-((R)-2-amino-3-phenylpropanamido)-3-phenylpropanamido)-4-methylpentanamido)hexanoyl)piperidine-4-carboxylic acid
Difelikefalin Dimer Impurity 1 is a specialized peptide derivative, structurally related to the parent compound difelikefalin, which is a synthetic peptide designed as a selective kappa-opioid receptor agonist. As an impurity dimer, this compound represents a molecular species formed through the association of two difelikefalin units, providing a unique biochemical profile that is highly relevant in the context of peptide synthesis, analytical method development, and quality control. Dimeric impurities such as this one are of particular interest in pharmaceutical research and manufacturing environments, where understanding and controlling byproduct formation is essential for ensuring the integrity and safety of peptide-based products.
Impurity profiling: In peptide research and pharmaceutical development, the presence of dimeric impurities is a critical quality attribute. Difelikefalin Dimer Impurity 1 serves as a reference standard for impurity profiling, enabling researchers and quality control laboratories to accurately identify, quantify, and monitor dimerization byproducts in peptide synthesis batches. Its use supports the establishment of robust analytical methods such as HPLC, LC-MS, and related chromatographic or spectrometric techniques, facilitating the detection and quantification of closely related molecular species.
Analytical method validation: The compound is instrumental in the validation of analytical procedures designed for the assessment of difelikefalin and its related substances. By incorporating the dimer impurity into method development workflows, laboratories can rigorously challenge the selectivity, sensitivity, and reproducibility of their assays. This practice ensures that analytical methods are capable of distinguishing between the active peptide and its structurally similar impurities, thereby enhancing data reliability and regulatory compliance in research and industrial settings.
Peptide stability studies: Dimeric impurities often arise as a result of peptide instability, aggregation, or side reactions during synthesis, storage, or formulation. Inclusion of Difelikefalin Dimer Impurity 1 in forced degradation and stability studies allows scientists to investigate the pathways and kinetics of dimer formation under various environmental and process conditions. Insights gained from these studies inform the optimization of peptide manufacturing protocols, storage guidelines, and formulation strategies to minimize impurity levels and maintain product quality.
Process optimization: Understanding the formation and behavior of dimeric byproducts is essential for refining peptide synthesis and purification processes. The availability of this specific dimer impurity enables process chemists and engineers to trace the origins of dimerization events, evaluate the impact of reaction parameters, and develop targeted strategies for impurity reduction. Such knowledge is crucial for improving overall yield, purity, and scalability in peptide production workflows.
Reference material for regulatory submissions: In the context of regulatory documentation and dossier preparation, well-characterized impurities like Difelikefalin Dimer Impurity 1 are often required as reference materials. Their inclusion allows for comprehensive impurity profiling and risk assessment, supporting the demonstration of process control and product safety to regulatory bodies. By providing a reliable standard for comparison, the dimer impurity facilitates transparent and scientifically robust submissions during drug development and manufacturing approval processes.
3. Myotropic activity of allatostatins in tenebrionid beetles
4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More